BR112013018565A2 - combinações - Google Patents
combinaçõesInfo
- Publication number
- BR112013018565A2 BR112013018565A2 BR112013018565A BR112013018565A BR112013018565A2 BR 112013018565 A2 BR112013018565 A2 BR 112013018565A2 BR 112013018565 A BR112013018565 A BR 112013018565A BR 112013018565 A BR112013018565 A BR 112013018565A BR 112013018565 A2 BR112013018565 A2 BR 112013018565A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- pharmaceutically acceptable
- acceptable salt
- ovarian cancer
- combinations
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 206010033128 Ovarian cancer Diseases 0.000 abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 2,3-dimethyl-2h-indazol-6-yl Chemical group 0.000 abstract 1
- BVAHPPKGOOJSPU-UHFFFAOYSA-N 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1NC1=CC(NC=2N(N=C(C)C=2)C(C)C)=NC=C1Cl BVAHPPKGOOJSPU-UHFFFAOYSA-N 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 abstract 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161436435P | 2011-01-26 | 2011-01-26 | |
| PCT/US2012/022638 WO2012103276A1 (en) | 2011-01-26 | 2012-01-26 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013018565A2 true BR112013018565A2 (pt) | 2016-09-27 |
Family
ID=46581159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013018565A BR112013018565A2 (pt) | 2011-01-26 | 2012-01-26 | combinações |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130296356A1 (https=) |
| EP (1) | EP2667871A4 (https=) |
| JP (1) | JP2014503589A (https=) |
| KR (1) | KR20140011322A (https=) |
| CN (1) | CN103476413B (https=) |
| AU (1) | AU2012209100A1 (https=) |
| BR (1) | BR112013018565A2 (https=) |
| CA (1) | CA2825790A1 (https=) |
| EA (1) | EA201391076A1 (https=) |
| IL (1) | IL227377A0 (https=) |
| MX (1) | MX2013008654A (https=) |
| SG (1) | SG191926A1 (https=) |
| WO (1) | WO2012103276A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013221298A1 (en) * | 2012-02-17 | 2014-08-28 | Pharmacyclics Llc | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
| WO2014059095A1 (en) * | 2012-10-12 | 2014-04-17 | Glaxosmithkline Llc | Combinations |
| CN104736154A (zh) * | 2012-10-22 | 2015-06-24 | 葛兰素史克公司 | 组合 |
| US20150306099A1 (en) * | 2012-11-27 | 2015-10-29 | Glaxosmithkline Llc | Combination |
| CN119451679A (zh) * | 2022-08-24 | 2025-02-14 | 应世生物科技(南京)有限公司 | Fak抑制剂及微管抑制剂的药物组合及用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034860B2 (en) * | 2006-07-21 | 2011-10-11 | Eastman Specialties Holdings Corporation | Organosol plastisol compositions |
| EP2727909A1 (en) * | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2009153589A1 (en) * | 2008-06-17 | 2009-12-23 | Astrazeneca Ab | Pyridine compounds |
| US20110301113A1 (en) * | 2008-09-26 | 2011-12-08 | Concert Pharmaceuticals Inc. | Pyridineamine derivatives |
| JO3067B1 (ar) * | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
-
2012
- 2012-01-26 EP EP12739192.8A patent/EP2667871A4/en not_active Withdrawn
- 2012-01-26 US US13/979,002 patent/US20130296356A1/en not_active Abandoned
- 2012-01-26 AU AU2012209100A patent/AU2012209100A1/en not_active Abandoned
- 2012-01-26 KR KR1020137022325A patent/KR20140011322A/ko not_active Withdrawn
- 2012-01-26 WO PCT/US2012/022638 patent/WO2012103276A1/en not_active Ceased
- 2012-01-26 EA EA201391076A patent/EA201391076A1/ru unknown
- 2012-01-26 MX MX2013008654A patent/MX2013008654A/es not_active Application Discontinuation
- 2012-01-26 BR BR112013018565A patent/BR112013018565A2/pt not_active IP Right Cessation
- 2012-01-26 CN CN201280013896.6A patent/CN103476413B/zh not_active Expired - Fee Related
- 2012-01-26 JP JP2013551318A patent/JP2014503589A/ja active Pending
- 2012-01-26 CA CA2825790A patent/CA2825790A1/en not_active Abandoned
- 2012-01-26 SG SG2013053178A patent/SG191926A1/en unknown
-
2013
- 2013-07-08 IL IL227377A patent/IL227377A0/en unknown
-
2015
- 2015-11-19 US US14/945,818 patent/US20160067248A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391076A1 (ru) | 2014-07-30 |
| KR20140011322A (ko) | 2014-01-28 |
| IL227377A0 (en) | 2013-09-30 |
| AU2012209100A1 (en) | 2013-08-01 |
| JP2014503589A (ja) | 2014-02-13 |
| SG191926A1 (en) | 2013-08-30 |
| MX2013008654A (es) | 2013-09-02 |
| EP2667871A1 (en) | 2013-12-04 |
| CN103476413A (zh) | 2013-12-25 |
| US20130296356A1 (en) | 2013-11-07 |
| CN103476413B (zh) | 2016-03-16 |
| WO2012103276A1 (en) | 2012-08-02 |
| CA2825790A1 (en) | 2012-08-02 |
| EP2667871A4 (en) | 2014-07-09 |
| US20160067248A1 (en) | 2016-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003654A1 (es) | Formulación farmaceutica estable para administracion intratecal que comprende una proteina arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que ademas puede contener un agente estabilizante; contenedor que comprende dicha formulacion; uso para tratar la enfermedad leucodistrofia metacromática (mld). | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| EP3501546A3 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
| BR112014010803A2 (pt) | método de tratamento | |
| BR112014009418A2 (pt) | macrociclos peptidomiméticos | |
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| MX2014008021A (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
| NZ598722A (en) | Methods for treating psoriasis | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| MY181928A (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| BR112013018565A2 (pt) | combinações | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112013017722A2 (pt) | combinação | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| EA201370162A1 (ru) | Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты | |
| BR112012027393A2 (pt) | composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
| BR112012008271A2 (pt) | combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |